Sign in

Jack Yongfeng Zhang

Chief Executive Officer at Amphastar Pharmaceuticals
Board
Since 1996
Age
78 years
Education
Holds a Ph.D. in Chemistry from the State University of New York at Stony Brook and was a Post-Doctoral Research Associate at the California Institute of Technology.
Tenure
Founded AMPH in 1996 and has served as the Chief Executive Officer, board member, and President (re-appointed in April 2020) while also acting as Chief Scientific Officer since 2005.

Also at Amphastar Pharmaceuticals

MZL
Mary Ziping Luo
Chief Operating Officer
WJP
William J. Peters
Chief Financial Officer, Executive Vice President of Finance, and Treasurer
JL
Jacob Liawatidewi
Executive Vice President of Sales and Marketing

About

Jack Yongfeng Zhang is a seasoned executive currently serving as the Chief Executive Officer at AMPH, with a comprehensive background in pharmaceutical innovation. He is 78 years old as of April 7, 2025.

He holds a Ph.D. in Chemistry from the State University of New York at Stony Brook and completed his post-doctoral research at the California Institute of Technology, marking a strong foundation in scientific research and development.

In his professional career, he co-founded AMPH in 1996, serving continuously as a board member and CEO since the company’s inception. His leadership encompasses roles as President—initially from 1996 until June 2013 and again from April 2020—and as Chief Scientific Officer since 2005, reflecting his deep involvement in both strategy and scientific advancement.

$AMPH Performance Under Jack Yongfeng Zhang

Past Roles

OrganizationRoleDate RangeDetails
Amphastar Pharmaceuticals (AMPH) President (First Term) 1996 - June 2013 Previously served as President before reappointment in April 2020
APCL President and Co-founder May 1989 - October 2002 Co-founded the company and led it until October 2002

Fixed Compensation

Data from  FY 2023
Component NameAmountPayment ScheduleAdditional Details
Salary$898,000 AnnualN/A
Bonus$310,847 AnnualN/A
All Other Compensation$59,909 Annual401(k) Company Contribution: $9,900; Vehicle Allowance: $35,243; Group Life Insurance Benefit: $4,944; Additional Medical Expenses: $9,822

Performance Compensation

Data from  FY 2023

Non-Equity Incentive Plan Compensation

The Non-Equity Incentive Plan Compensation for 2023 is performance-based and contingent on achieving specified performance metrics. The payout ranges based on performance are outlined below.

Threshold ($)Target ($)Maximum ($)
$497,000 $621,000 $931,000

Performance Metrics and Targets

Performance is measured against five key metrics. Bonuses are paid only if the minimum thresholds are met and increase as results move from target to stretch and super-stretch levels.

Performance CriteriaMinimumTargetStretchSuper Stretch
Sales Growth on Budget vs. 20221.0% - 5.0% 5.1% - 10.0% 10.1% - 15.0% > 15%
Stock Price Appreciation (12/31/22 - 12/31/23)10% 15% 20% 25%
Filing of an ANDA, NDA, or BLA progress1 2 3 > 3
Approval of ANDA or NDA1 2 3 > 3
General Corporate Goals1 2 3 > 3

Additional Details:

  • Evaluation Period: March 2023 through February 2024.
  • Eligibility: Continued service and the achievement of the outlined performance metrics.
  • Vesting Schedule: Not applicable since payouts are determined solely on performance outcomes.